8-K: Assertio Holdings Sets Tender Offer Date for Acquisition

Assertio Holdings announced that Garda Therapeutics will commence a tender offer to acquire all outstanding shares for $18.00 per share on April 29, 2026.

Summary

• Assertio Holdings, Inc. entered into a definitive merger agreement with Garda Therapeutics, Inc. on April 8, 2026.
• The acquisition price is set at $18.00 per share in cash, totaling approximately $125.1 million, plus a contingent value right.
• The agreement includes a 20-day window-shop period allowing Assertio to solicit superior bids.
• Garda Therapeutics intends to commence the formal tender offer on April 29, 2026, immediately following the expiration of the window-shop period.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development for shareholders as it provides a definitive path to liquidity at a set cash price, though the deal remains subject to standard closing risks.

Positives

• The offer price of $18.00 per share provides a clear exit valuation for shareholders.
• The inclusion of a contingent value right offers potential additional upside for shareholders.
• The window-shop provision allows the Board to continue seeking superior value for shareholders during the transition period.

Negatives

• The company is currently subject to a 20-day window-shop period, creating uncertainty regarding the finality of the deal.
• The transaction is subject to various closing conditions and regulatory approvals that could delay or prevent completion.

Risks

• The possibility that the transaction fails to close due to unmet conditions or regulatory intervention.
• The risk that competing offers may not materialize or may be deemed insufficient.
• Potential disruption to business operations and employee retention during the pendency of the merger.
• The risk that contingent value right milestones are not achieved, resulting in no additional payments to shareholders.

Future Outlook

The company expects the tender offer to commence on April 29, 2026, following the expiration of the window-shop period, provided all conditions are met.

Management Comments

• Management confirmed the intent to proceed with the tender offer following the expiration of the window-shop period on April 28, 2026.

Industry Context

StockSavvy.ai notes that this acquisition reflects ongoing consolidation trends in the mid-cap pharmaceutical sector, where companies with specific commercial capabilities are being targeted by private or specialized entities to streamline oncology portfolios.

Comparison to Industry Standards

• The $125.1 million valuation is consistent with recent small-to-mid-cap pharmaceutical take-privates.
• The inclusion of a contingent value right (CVR) is a standard mechanism in biotech M&A to bridge valuation gaps between buyers and sellers regarding pipeline assets.

Legal Proceedings

• The filing notes the potential for legal proceedings related to the transaction, which is standard for public company mergers.

Stakeholder Impact

• Shareholders: Expected to receive $18.00 per share in cash upon successful completion of the tender offer.
• Employees: Potential uncertainty regarding future roles and organizational structure post-merger.

Next Steps

• Expiration of the 20-day window-shop period on April 28, 2026.
• Commencement of the tender offer on April 29, 2026.
• Filing of Schedule TO by Garda and Schedule 14D-9 by Assertio with the SEC.

Key Dates

Recommendation

Investors should hold shares until the tender offer materials are filed and the window-shop period concludes to ensure no superior bids emerge.

Keywords

Assertio Holdings, Garda Therapeutics, Merger, Tender Offer, ASRT, Acquisition, Pharmaceuticals